|
Apr 28
|
Stocks Rise in Final Hour of Wall Street Trading: Markets Wrap
|
|
Apr 28
|
Johnson & Johnson (JNJ): Among the Most Profitable Blue Chip Stocks to Buy Now
|
|
Apr 28
|
Google Parent Alphabet Leads US High-Grade Issuance Rush
|
|
Apr 28
|
CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug
|
|
Apr 28
|
New data from J&J’s bladder cancer drug-device trial strengthens support for NDA
|
|
Apr 28
|
Jim Cramer Says Trump Administration Should Intervene in Johnson & Johnson (JNJ) Legal Issues – ‘Where Are Capitalist Instincts Here?’
|
|
Apr 28
|
J&J’s Tremfya gains EC marketing authorisation for ulcerative colitis
|
|
Apr 27
|
Jim Cramer Says You Should Buy Johnson & Johnson (JNJ), Thinks Talc Problems ‘Behind It’
|
|
Apr 26
|
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
|
|
Apr 26
|
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
|
|
Apr 26
|
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
|
|
Apr 26
|
Is Johnson & Johnson (JNJ) the Best Safe Stock to Buy According to Hedge Funds?
|
|
Apr 25
|
Johnson & Johnson (JNJ) Soared as Markets Favored Defensive Sector
|
|
Apr 24
|
3 Dividend Kings That Have Raised Their Payouts in 2025
|
|
Apr 24
|
In the Wake of the Trump Tariff Crash: 2 Unparalleled Dividend Stocks to Buy at a Discount Right Now
|
|
Apr 24
|
Jim Cramer on Johnson & Johnson (JNJ): ‘A Good Quarter — Market Finally Cares’
|
|
Apr 23
|
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
|
|
Apr 23
|
European pharma companies push for higher drug prices in EU amid U.S. tariff threats
|
|
Apr 23
|
JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations
|
|
Apr 15
|
Johnson & Johnson Skids Despite First-Quarter Beat, Sales Guidance Hike
|